For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Revenues | 0 | 0 | ||
| Cost of revenue | 0 | 0 | ||
| Gross profit | 0 | 0 | ||
| Research and development expense | 1,643,000 | 1,520,000 | ||
| General and administrative expense | 1,613,000 | 1,148,000 | ||
| Net expenses related to opko collaboration agreement | 3,256,000 | 2,668,000 | ||
| Operating loss | -3,256,000 | -2,668,000 | ||
| Financial income, net | 56,000 | 12,000 | ||
| Net loss | -3,200,000 | -2,656,000 | ||
| Earnings per share, basic and diluted | 0.07 | 0.06 | ||
| Earnings per share, diluted | 0.07 | 0.06 | ||
| Weighted average number of shares outstanding, basic and diluted | 47,089,814 | 46,836,700 | ||
| Weighted average number of shares outstanding, diluted | 47,089,814 | 46,836,700 | ||
Entera Bio Ltd. (ENTXW)
Entera Bio Ltd. (ENTXW)